International Agency for Research on Cancer (IARC) - Summaries & Evaluations
VOL.: 40 (1986) (p. 317)
CAS No.: 20073-24-9
Chem. Abstr. Name: 7-Oxo-7H-furo[3,2-g]benzopyran-6-carboxylic acid, ethyl ester
5. Summary of Data Reported and Evaluation
There is no known human exposure to 3-carbethoxypsoralen, other than
in limited clinical trials for the treatment of psoriasis.
5.2 Experimental data
3-Carbethoxypsoralen was tested for skin carcinogenicity in two
experiments in two strains of mice by skin application with and
without ultraviolet A radiation and in one study in mice by
intraperitoneal administration with subsequent ultraviolet A
radiation. No skin tumour was observed in 3-carbethoxypsoralen-treated
mice in any of the three studies, with ultraviolet A radiation. The
studies were inadequate to evaluate the systemic carcinogenicity of
No data were available to evaluate the reproductive effects or
prenatal toxicity of 3-carbethoxypsqpen to experimental animals.
In the presence of ultraviolet A radiation, 3-carbethoxypsoralen bound
covalently to isolated DNA and induced DNA damage in Salmonella
typhimurium, Escherichia coli and Saccharomyces cerevisiae. It was not
mutagenic to Salmonella typhimurium in the dark in the absence of an
exogenous metabolic system. In combination with ultraviolet A
radiation, 3-carbethoxypsoralen induced mutations and mitotic
recombination in yeast and mutations and sister chromatid exchanges in
cultured mammalian cells in vitro.
5.3 Human data
No case report or epidemiological study of the carcinogenicity of
3-carbethoxypsoralen was available to the Working Group.
On the basis of experiments designed to test only the carcinogenicity
to mouse skin of 3-carbethoxypsoralen in combination with ultraviolet
A radiation, there is no evidence of carcinogenicity to experimental
There is inadequate evidence for the carcinogenicity to
experimental animals of 3-carbethoxypsoralen in the absence of
ultraviolet A radiation.
No evaluation could be made of the carcinogenicity of
3-carbethoxypsoralen to humans.
For definition of the italicized terms, see Preamble Evaluation.
Subsequent evaluation: Suppl. 7 (1987) (p. 59: Group 3)
- Ethyl 7-oxo-7H-furo[3,2-g][l]benzopyran-6-carboxylate
- Ethyl 3-psoralencarboxylate
- 6-Hydroxy-5-benzofuranyl)methylene]malonic acid, d-lactone, ethyl ester
Last updated: 22 April 1998